SCHEMBL6845459

SCHEMBL6845459

Cc1ccncc1-n1ccc2c(-c3cccc(F)c3)cccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 1/20 0.41
GRIN1 Q05586 2/20 0.41
GRIN2B Q13224 2/20 0.41
CYP17A1 P05093 8/20 0.41
CYP1A2 P05177 4/20 0.41
SLC22A12 Q96S37 1/20 0.40
CYP11B1 P15538 2/20 0.36
CYP11B2 P19099 1/20 0.36
QPCT Q16769 1/20 0.36
CDC7 O00311 1/20 0.36
ROCK2 O75116 1/20 0.36
MAP4K4 O95819 1/20 0.36
PIM1 P11309 1/20 0.36
PRKACA P17612 1/20 0.36
CDK2 P24941 1/20 0.36
GSK3B P49841 1/20 0.36
HIPK2 Q9H2X6 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36
IRAK4 Q9NWZ3 1/20 0.36
DGAT2 Q96PD7 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6656515 0.87 CYP17A1 (0.47) DHODHCYP17A1CYP1A2HSD11B1
SCHEMBL6661647 0.85 MAPK14 (0.44) CYP17A1CYP1A2CYP11B1CYP11B2CDC7
SCHEMBL6657600 0.83 CYP11B1 (0.43) CYP17A1CYP1A2SLC22A12CYP11B1CYP11B2
SCHEMBL6661929 0.81 MET (0.42) CYP1A2QPCTGSK3BMAPT
SCHEMBL6840591 0.81 CYP17A1 (0.52) CYP17A1CYP1A2
SCHEMBL6845971 0.81 SETD7 (0.41) CYP17A1CYP1A2SLC22A12HSD11B1
SCHEMBL6658314 0.80 MAPT (0.44) GRIN1GRIN2BCYP17A1CYP11B1CYP11B2
SCHEMBL6844416 0.79 CDC7 (0.41) CYP17A1CYP1A2CDC7CDK2
SCHEMBL6844285 0.78 CYP11B2 (0.42) CYP17A1CYP1A2SLC22A12CYP11B1CYP11B2
SCHEMBL6659801 0.76 CYP1A2 (0.40) GRIN1GRIN2BCYP1A2SLC22A12CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040236110-A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors BAYER PHARMACEUTICALS CORPORATION 2004-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040236110-A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors CYP17A1, IDO1, CYP21A2 DHODH 121/4885GRIN1 3702/4885GRIN2B 4156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.